AC
TARS icon

AlphaCore Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

AlphaCore Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,750
Closed -$716K – 1485
2025
Q4 		$716K Sell
8,750
-1,350
-13% -$101K 0.02% 501
2025
Q3 		$600K Sell
10,100
-2,000
-17% -$98.5K 0.02% 411
2025
Q2 		$490K Buy
+12,100
New +$545K 0.02% 375

Other funds holding TARS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

AlphaCore Capital's TARS Position: Q1 2026 in Review

AlphaCore Capital sold out of Tarsus Pharmaceuticals (TARS) in Q1 2026, closing a stake of 8,750 shares — an estimated $716K sold.

AlphaCore Capital first reported a position in TARS in Q2 2025 and held it in 3 quarters. The position peaked at $716K in Q4 2025. 253 funds tracked by Wall St. Rank hold TARS as of Q1 2026.

  • AlphaCore Capital reported no remaining Tarsus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • AlphaCore Capital sold 8,750 Tarsus Pharmaceuticals shares in Q1 2026, an estimated $716K.
  • AlphaCore Capital first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • AlphaCore Capital's Tarsus Pharmaceuticals position peaked at $716K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.